sclareol has been researched along with Lung Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, HL; Chiang, YC; Gong, JY; Hung, JH; Li, S; Lin, CC; Lin, SC; Yen, CC | 1 |
| Chen, SY; Huang, HY; Pan, CH; Tsao, SP; Wang, JY; Wei-Chen Chiu, P; Wu, CH | 1 |
2 other study(ies) available for sclareol and Lung Neoplasms
| Article | Year |
|---|---|
Effects of Sclareol Against Small Cell Lung Carcinoma and the Related Mechanism:
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Diterpenes; DNA Damage; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Signal Transduction; Small Cell Lung Carcinoma; Treatment Outcome; Xenograft Model Antitumor Assays | 2020 |
Sclareol ameliorated ERCC1-mediated cisplatin resistance in A549 human lung adenocarcinoma cells and a murine xenograft tumor model by suppressing AKT-GSK3β-AP1/Snail and JNK-AP1 pathways.
Topics: A549 Cells; Adenocarcinoma of Lung; Animals; Cell Movement; Cisplatin; Diterpenes; Drug Resistance, Neoplasm; Drug Synergism; Glycogen Synthase Kinase 3 beta; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Models, Biological; Proto-Oncogene Proteins c-akt; Replication Protein C; Snail Family Transcription Factors; Transcription Factor AP-1; Xenograft Model Antitumor Assays | 2020 |